-
Mashup Score: 5EBMT 2023 | VJHemOnc - 1 year(s) ago
The 49th Annual Meeting of the EBMT 23–26 April 2023 | Paris, France / Online VJHemOnc is pleased to be a Media Partner for the 49th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) that was held in Paris, France, and online, on 23 – 26 April 2023. This meeting brought…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0CARBON: results of Phase I study of CTX110 allogeneic CRISPR-CAS9-engineered CAR-Ts in R/R LBCL - 1 year(s) ago
Joseph McGuirk, DO, The University of Kansas Medical Center, Kansas City, KS, comments on the design and advantages of CTX110,…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Joseph McGuirk (@KUMedCenter) shares some results from the Phase I CARBON study, which is evaluating CTX110 in patients with R/R LBCL. Watch here: 🎥 https://t.co/dVAcGOPLZd @TheEBMT #EBMT23 #LymSM #ImmunoOnc #DLBCL
-
-
Mashup Score: 2Bringing CAR-T therapy in earlier lines of treatment in myeloma: KarMMa-3, CARTITUDE-4 & CARTITUDE-6 - 1 year(s) ago
Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, shares his enthusiasm for the advent of the two approved CAR-T therapies…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#EBMT23 | @Mohty_EBMT discusses the current status of CAR-T therapy in myeloma & highlights clinical trials evaluating these agents in earlier lines, including KarMMa-3 and CARTITUDE-4: 🎥 https://t.co/CgQSwwp94g @TheEBMT #MMsm #HemOnc #ImmunoOnc
-
-
Mashup Score: 0Optimizing the treatment of transplant-eligible NDMM: using quadruplets in induction & consolidation - 1 year(s) ago
Elias Mai, MD, University Hospital Heidelberg, Heidelberg, Germany, comments on the benefit of autologous transplantation and quadruplets in the induction…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#EBMT23 | @EliasKarlMai shares some insights into how to optimize treatment in transplant-eligible NDMM with the use of quadruplets in induction & consolidation. Watch here: 🎥 https://t.co/X8QOlJGtkd @TheEBMT #MMsm #BMTsm #HemOnc
-
-
Mashup Score: 6EBMT 2023 | VJHemOnc - 1 year(s) ago
The 49th Annual Meeting of the EBMT 23–26 April 2023 | Paris, France / Online VJHemOnc is pleased to be a Media Partner for the 49th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) that was held in Paris, France, and online, on 23 – 26 April 2023. This meeting brought…
Source: VJHemOncCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @VJHemOnc: Missed #EBMT23? Don't worry! Find all the important updates shared at the meeting here: 👉https://t.co/F0qGqaNDcM👈 @TheEBMT…
-
-
Mashup Score: 0
Evelyn Ullrich, MD, PhD, Goethe University Frankfurt, Frankfurt, Germany, shares her excitement for novel technologies to engineer natural killer (NK)…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Tune in to our exclusive interview with Evelyn Ullrich (@Ullrich_Lab) who discusses advances in gene engineering for NK cell-based immunotherapy: 🎥 https://t.co/hzZa7eUMiv @TheEBMT #EBMT23 #ImmunoOnc
-
-
Mashup Score: 3EBMT 2023 | VJHemOnc - 1 year(s) ago
The 49th Annual Meeting of the EBMT 23–26 April 2023 | Paris, France / Online VJHemOnc is pleased to be a Media Partner for the 49th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) that was held in Paris, France, and online, on 23 – 26 April 2023. This meeting brought…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Missed #EBMT23? Don't worry! Find all the important updates shared at the meeting here: 👉https://t.co/F0qGqaNDcM👈 @TheEBMT @TheEBMT_Nurses @TheEBMT_Trainee @Mohty_EBMT @AnnaSureda5 #BMTsm #CART https://t.co/cAhSCgWajR
-
-
Mashup Score: 3The evolution of stem cell transplantation - 1 year(s) ago
Norbert-Claude Gorin, MD, PhD, Saint-Antoine Hospital and Sorbonne University, Paris, France, gives an overview of the main changes that have…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Norbert-Claude Gorin (@HopSaintAntoine) gives an overview of how stem cell transplantation has evolved over the years, commenting on changes in stem cell source, conditioning regimens & more: 👉https://t.co/rFHStZMLV6👈 @TheEBMT #EBMT23 #BMTsm #HemOnc
-
-
Mashup Score: 0
Christian Chabannon, MD, PhD, Paoli-Calmettes Institute, Marseille, France, comments on the current status of CAR-T therapy in the second-line treatment…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#EBMT23 | @CChabannon discusses the current status of CAR-T therapy in second-line #DLBCL in Europe. Watch his interview here: 🎥: https://t.co/LSlW6p0PIY @TheEBMT #CARTcell #LymSM #ImmunoOnc
-
-
Mashup Score: 1Using bispecific antibodies instead of chemotherapy to reach pre-transplant remission in B-ALL - 1 year(s) ago
Christina Peters, MD, St. Anna Children’s Hospital, Vienna, Austria, comments on the benefits of reducing or substituting chemotherapy with bispecific…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#EBMT23 | We caught up with Christina Peters (@StAnna_CCRI), who spoke on the benefits of substituting chemotherapy with bispecifics before alloSCT in pediatric patients with B-ALL: 👉https://t.co/lOybOATOvP👈 @TheEBMT #LeuSM #ALLsm #BMTsm #ImmunoOnc
-
So much exciting content was shared at this year's #EBMT23! Discover the key updates here: 👉https://t.co/xRc6oCBevR👈 @TheEBMT @TheEBMT_Nurses @TheEBMT_Trainee @Mohty_EBMT @AnnaSureda5 #BMTsm #CART #HemOnc #ImmunoOnc https://t.co/vUYYNKNN5w